All Oncology News

Nancy E. Kemeny, MD, discusses the combination of pump and systemic therapy as a liver-directed treatment option for patients with metastatic colorectal cancer.

Diane Reidy-Lagunes, MD, discusses ongoing developments for the treatment of patients with gastrointestinal and pancreatic NETs.

The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

Ravi Salgia, MD, PhD, discusses the evolution and current state of biomarker testing in the field of NSCLC.

Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.

The FDA has granted a breakthrough therapy designation to eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia.

Nearly 7 in 10 patients with locally advanced or metastatic BRAF V600E–mutated anaplastic thyroid cancer responded to treatment with the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.

Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).

Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.

Miami Cancer Institute at Baptist Health will leverage Cota's data, nodal address and analytics to deliver precision medicine and enable the best treatments at the highest quality of care for patients.

Dan J. Raz, MD, discusses the ongoing ALCHEMIST trial and some novel techniques, such as tissue slice culture, that are propelling the field of lung cancer forward.

The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with BRAF-mutated and wild-type histiocytic disorders.

In patients with stage III favorable-histology Wilms tumor, negative nodal involvement and the absence of loss of heterozygosity at chromosomes 1p and 16q were predictors for event-free survival and overall survival.

More than one-quarter of patients with relapsed/refractory mantle cell lymphoma remained progression free and nearly half were alive at 3 years when treated with the BTK inhibitor ibrutinib (Imbruvica).

The FDA has granted ribociclib a breakthrough therapy designation for use in combination with tamoxifen or an aromatase inhibitor as frontline treatment for pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.

The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) in combination with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for advanced classical Hodgkin lymphoma.

Loretta Erhunmwunsee, MD, discusses the racial and socioeconomic disparities in lung cancer trials

Adam M. Brufsky, MD, PhD, discusses the developing role of pertuzumab in HER2-positive breast cancer, as well as the impact of other agents in the field.

Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).

Luis A. Diaz, MD, discusses the precision medicine approaches available and in development for the treatment of patients with GI malignancies.

Jared Weiss, MD, discusses utilizing liquid biopsies for patients with lung cancer, the pros and cons of the approach, and when it might be appropriate to rebiopsy patients.

The FDA has granted a priority review designation to a novel version of the radiopharmaceutical iobenguane I-131 for patients with malignant or recurrent pheochromocytoma or paraganglioma.

Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.

The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.

Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.

Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.

Daniel E. Haggstrom, MD, discusses the developing area of immunotherapy combinations for patients with non-small cell lung cancer.

Erika P. Hamilton, MD, discusses recent FDA approvals in the treatment paradigm of HER2-positive breast cancer.

Robert L. Coleman, MD, discusses targeting tumor vasculature and angiogenesis in ovarian cancer.